The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically
Over the Next Ten Years Due to the Launch of New Therapies in the United
States and EU5
Both Incident Cases of and Drug-Treatment Rates for Hepatocellular Carcinoma
Will Increase throughout the Forecast Period, According to Findings from
BURLINGTON, Mass., Jan. 29, 2013
BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that the treatment landscape for hepatocellular
carcinoma in the United States and Europe will change dramatically through
2021 as three new, potentially high priced therapies–Novartis's Afinitor,
ArQule's tivantinib and Celsion's ThermoDox–arrive on the market, thereby
greatly increasing treatment options in patient populations in which there is
no approved standard-of-care drug therapy.
According to Niche Markets and Rare Diseases: Hepatocellular Carcinoma, of the
forecasted emerging therapies, Afinitor will be the first drug to gain
regulatory approval and will launch in 2014 in all markets under study for
treatment of advanced hepatocellular carcinoma in the second-line setting
following disease progression on Bayer HealthCare/Onyx Pharmaceuticals'
Nexavar, the current patient-share leader. By 2021, tivantinib will also
launch in the second-line setting for treatment of patients who express high
levels of c-MET. ThermoDox, a heat-sensitive liposome-encapsulated formulation
of doxorubicin, will be the only therapy to launch over the next ten years in
the localized/locally advanced setting for use in combination with
radiofrequency embolization (RFA).
"According to opinion leaders, one of the greatest unmet needs in the
hepatocellular carcinoma space is for a second-line therapy directed at
patients who cannot tolerate treatment with or progress on Nexavar–the
standard-of-care in the first-line setting through 2021," said Decision
Resources Analyst Karen Pomeranz, Ph.D. "However, the launch of ThermoDox will
herald a novel treatment approach in localized/locally advanced disease. Most
interviewed physicians are excited by this prospect because it could
potentially increase the benefit of treatment with RFA for patients with
disease confined to the liver and could also lead to an increase in treatment
rates with RFA—particularly in the locally advanced setting."
In addition, the findings reveal that the number of incident cases of
hepatocellular carcinoma in the major markets will increase by approximately
30 percent over the forecast period, driven by an aging population and an
overall increase in risk. Drug treatment rates will also rise as new therapies
come to market.
About Hepatocellular Carcinoma
Hepatocellular Carcinoma is offered as part of Decision Resources' Niche
Markets and Rare Diseases service. Each report assesses opportunity in a
select drug market across the United States, France, Germany, Italy, Spain and
the United Kingdom. The report provides detailed coverage of patient
populations, current therapies, unmet needs and emerging therapies, and
includes primary research with country-specific thought leaders.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Decision Resources Group
Allison Thrower Liz Marshall
SOURCE Decision Resources
Press spacebar to pause and continue. Press esc to stop.